

disorder, a differentiative disorder, and a glia-associated disorder, wherein said therapeutic is the nucleic acid of claim 1.

Insert the following claims:

-- 28. An isolated nucleic acid molecule encoding FGF-CX, said molecule comprising a nucleotide sequence selected from the group consisting of:

- a) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO:1;
- b) a fragment of a nucleic acid sequence comprising a nucleic acid sequence of SEQ ID NO:1, wherein the fragment comprises at least 6 contiguous nucleotides of SEQ ID NO:1;
- c) a derivative of a nucleic acid comprising a nucleic acid sequence of SEQ ID NO:1;
- d) an analog of a nucleic acid comprising a nucleic acid sequence of SEQ ID NO:1;
- e) a homolog of a nucleic acid comprising a nucleic acid sequence of SEQ ID NO:1; and
- f) a naturally occurring allelic variant of a nucleic acid of SEQ ID NO:1, wherein the nucleic acid hybridizes to a nucleic acid molecule of SEQ ID NO:1 under stringent conditions.

29. The nucleic acid of claim 28 wherein the nucleic acid, or a fragment thereof, has an activity selected from the group consisting of:

- a) a fibroblast growth factor-like activity;
- b) a cell proliferative activity;
- c) a glia activating activity; and
- d) a neuroprotective-like activity. --

### RESPONSE TO RESTRICTION REQUIREMENT

Applicants elect Group I, Claims 1-10, 14 and 19-21, drawn to polynucleotides, vectors, host cells and methods of making a polypeptide, classified in class 435, subclass 69.4, for example. Applicants make all elections without prejudice to pursuing non-elected subject matter in later applications. This election is being made without traverse.

### REMARKS

Upon entry of the present amendments, claims 1-10, 14, 19-21 and 28-29 are pending.